Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-12-26
2006-12-26
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S003100, C530S308000, C530S322000, C530S402000, C530S391900, C424S278100
Reexamination Certificate
active
07153825
ABSTRACT:
We claim a method of lowering plasma glucagon in a subject in need thereof comprising administering to the subject a composition comprising a modified exendin or modified exendin analog, wherein said modification comprises one or more molecule linked to an exendin or the exendin analog wherein said molecule is selected from the group consisiting of polyethylene glycol, gelatin and/or albumin. The modified exendin or the modified exendin analog has activity of suppressing glucagon secretion and/or lowering glucagon levels in the subject and possesses increased biological half-life compared to unmodified exendin or unmodified exendin analog. The method is useful in treating hyperglucagonemia and other disorders that would be benefited by lowering plasma glucagon or suppressing glucagon secretion.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 5264372 (1993-11-01), Beaumont et al.
patent: 5424286 (1995-06-01), Eng
patent: 5686511 (1997-11-01), Bobo
patent: 5839443 (1998-11-01), Rose et al.
patent: 6051557 (2000-04-01), Drucker
patent: 6376549 (2002-04-01), Fine et al.
patent: 6924264 (2005-08-01), Prickett et al.
patent: 2005/0026834 (2005-02-01), Cox et al.
patent: 199731732 (1998-01-01), None
patent: WO 95/07098 (1995-03-01), None
patent: WO9746584 (1997-12-01), None
patent: WO 98/05351 (1998-02-01), None
patent: WO 98/30231 (1998-07-01), None
patent: WO9830231 (1998-07-01), None
patent: WO 99/07404 (1999-02-01), None
patent: WO 99/25727 (1999-05-01), None
patent: WO 99/25728 (1999-05-01), None
patent: WO 99/40788 (1999-08-01), None
patent: WO 00/41546 (2000-07-01), None
patent: WO 00/41548 (2000-07-01), None
Varshavsky, A. (1997) The ubiquitin system. Trends Biochem. Sci. vol. 22, No. 10, pp. 383-387.
Holst, J. J. (2004) Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.□□Expert Opin Emerg Drugs. vol. 9, No. 1, pp. 155-166. Review.
Lefebvre et al. (1979) Glucagon and diabetes: a reappraisal. Diabetologia, vol. 16, No. 6, pp. 347-354.
Delgado et al. (1992) The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. vol. 9, issues 3-4, pahes 249-304.
Byrne, M.M., et al., “Lessons from Human Studies with Glucagon-like Peptide-1: Potential of the Gut Hormone for Clinical Use,”Front. Diabetes, 13:219-33 (1997).
Chen, Y. E., et al., “Tissue-specific Expression of Unique mRNAs That Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard,”Journal of Biological Chemistry, 272 (7) :4108-4115 (1997).
Creutzfeldt, W. O. C., et al., “Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-like Peptide I(7-36) Amide in Type I Diabetic Patients,”Diabetes Care19 (6):580-6 (1996).
D'Alessio, et al., “Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons,”J. Clin. Invest., 97:133-38 (1996).
Egan, J.M., et al., “Glucagon-like Peptide-1 Restores Acute Phase Insulin Release to Aged Rats,”Diabetologia, 40(Supp 1) :A130 abstract 505 (1997).
Daniel, O. et al., “Use of Glucagon in the Treatment of Acute Diverticultis,”British Medical Journal, 3:720-2, (1974).
Eissele, et al., “Rat Gastric Bomatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-like Peptide-1 (GLP-1) Amide,”Life Sci., 55(8) :629-34 (1994).
Eng, J., et al., “Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated fromHeloderma horridumVenom,”J. Biol. Chem., 265(33) :20259-62 (1990).
Eng, J., et al., “Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, fromHeloderma suspectumVenom,”J. Biol. Chem., 267(11) :7402-05 (1992).
Eng, J., “Prolonged Effect of Exendin-4 on Hyperglycemia of db/db mice,”Diabetes, 45(Supp 2) :152A (abstract 554) (1996).
Francis, et al., “PEGylation of Cytokines and Other Therapeutic Proteins and Peptides: the Importance of Biological Optimisation of Coupling Techniques,”International Journal of Hematology, 68(1) :1-18 (1998).
Glaüser, et al., “Intravenous Glucagon in the Management of Esophageal Food Obstruction,”JACEP, 8:228-231 (1979).
Goke, et al. “Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β-Cells,”J. Biol. Chem., 268(26) :19650-55 (1993).
Malhotra, et al., “Exendin-4, a New Peptide fromHeloderma SuspectumVenom, Potentiates Cholecystokinin-Induced Amylase Release from Rat Pancreatic Acini,”Regulatory Peptides, 41:149-56 (1992).
O'Halloran, et al., “Glucagon-like Peptide-1 (7-36)-NH2: A Physiological Inhibitor of Gastric Acid Secretion in Man,”J. Endocrinol. 126(1) :169-73 (1990).
Ørskov, et al., “Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable,”Diabetes, 42:658-61 (1993).
Passa, P., et al., “Mechanisms Suppressing Glucagon Secretion in Glucagonomas”Diabetologia, 19(3) :305 (abstract 298) (1980).
Raufman, et al. “Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas,”J. Biol. Chem., 267(30) :21432-37 (1992).
Schepp, et al., “Exendin-4 and Exendin-(9-39) NH2: Agonist and Antagonist, Respectively, at the Rat Parietal Cell Receptor for Glucagon-like Peptide-1-(7-36)NH2,”Eur. J. Pharm., 269:183-91 (1994).
Schioldager, et al., “GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans,”Dig. Dis. Sci., 34(5):703-8 (1989).
Singh, et al., “Use of125I-[Y39] exendin-4 to Characterize Exendin Receptors on Dispersed Pancreatic Acini and Gastric Chief Cells from Guinea Pig,”Regul. Pep., 53:47-59 (1994).
Stower, et al., “A Trial of Glucagon in the Treatment of Painful Biliary Tract Disease,”Br. J. Surg., 69:591-2 (1982).
Thorens, “Expression Cloning of the Pancreatic β Cell Receptor for the Gluco-Incretin Hormone Glucagon-like Peptide 1,”Proc. Natl. Acad. Sci. USA, 89:8641-45 (1992).
Turton, M.D., et al., “A Role for Glucagon-like Peptide-1 in the Central Regulation of Feeding,”Nature, 379:69-72 (1996).
Wettergren, et al., “Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man,”Dig. Dis. Sci., 38(4):665-73 (1993).
Willms, et al., “Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Mal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients,”J. Clin. Endocrinol. Metab., 81(1):327-32 (1996).
Bloom, S.R. et al. (1987) “Glucagonoma syndrome” Am. J. Med. vol. 82, pp. 25-36.
Parhes, D.G. et al. (2001) “Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro” Metabolis, vol. 50, pp. 583-589.
Drucker, D.J. (1998) “Glucaton-like peptides” Diabetes, vol. 47, pp. 159-169.
Markletter, Aug. 24, 1998 (p. n/a).
Gedulin Bronislava
Young Andrew A.
Amylin Pharmaceuticals Inc.
Liu Samuel W.
Weber Jon
LandOfFree
Methods for glucagon suppression using modified exendins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for glucagon suppression using modified exendins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for glucagon suppression using modified exendins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3702547